Giving Process Its Due When An SDO Changes Rules Of The Game 22/01/2017 by Intellectual Property Watch 1 Comment George Willingmyre writes: The process a Standards Developing Organization (SDO) employs to revise its patent policy is an aspect of the SDO’s competitive posture in the global marketplace. A dearth of research exists on the processes SDOs employ to revise their patent policies. Generally, the processes an SDO uses to revise its patent policy are part of the governance processes of the SDO. As a baseline, the governance processes of an SDO must be consistent with the applicable legal system defining what is acceptable and unacceptable behavior. What an SDO says about its governance processes is a further consideration. Thus the procedures themselves, the procedures’ relationship to the applicable legal system and what the SDO says about the procedures all play a role in understanding how an SDO revises its patent policy.
Expensive Medicines Increase The Pressure 09/01/2017 by Intellectual Property Watch 1 Comment When Gilead brought its new antiviral medicine – Sovaldi – for the treatment of Hepatitis C to the US market for USD 84,000, it triggered a storm of protest. Demand for this revolutionary treatment was so high that the price (despite reductions) became an enormous burden on the American healthcare system. Although the product is cheaper in Switzerland at CHF 48 307, treatment is rationed for reasons of cost.
TPP May Be Dead – But Its Impact Lingers 06/12/2016 by Intellectual Property Watch 3 Comments Despite the Trans-Pacific Partnership (TPP) being – to all-intents-and-purposes – dead in the water, pursuit of some of the most egregious objectives of the corporate interests driving the TPP agenda rolls on. Pharma is persisting in its push for countries to adopt not just TRIPS-Plus, but in some cases even TPP-Plus intellectual property rules – presumably groundwork for the later emergence of a ‘son-of-TPP’ agreement, three authors write.
WHO Makes Headway In Hepatitis C Treatment Access Campaign 07/11/2016 by Intellectual Property Watch Leave a Comment Daniele Dionisio writes: It is morally mandatory to ensure that lifesaving direct-acting antivirals for hepatitis C treatment become accessible to all those who need them. This requires commitment and coordination by all interested parties to overcome barriers to access.
Protecting Online Access To Safe And Affordable Medication 27/10/2016 by Intellectual Property Watch Leave a Comment High drug prices are a global public health crisis. This is mostly the case among lower income countries but also for citizens and residents in the US, where tens of millions are not filling prescriptions due to cost. The international online marketplace is a much-needed lifeline for consumers who cannot afford prescription medication where they live. People deserve the widest possible access to safe and affordable medication, including online access, and the Internet community can help, says Gabriel Levitt.
Which “Brazil” Will Chair The Marrakesh Treaty Assembly? 11/10/2016 by Intellectual Property Watch 1 Comment The supposedly impossible happened: The Marrakesh Treaty entered into force on 30 September, three months after reaching the necessary minimum of 20 ratifications. By then, 22 countries had done so – two more did so during the Marrakesh Assembly.
Delinkage Of R&D Costs From Product Prices 15/09/2016 by Intellectual Property Watch 5 Comments It is essential that policy makers reform the systems for financing R&D, and de-link the costs of R&D from the prices of products, says James Love.
Shifting Mindsets To Improve Access To Medicine 13/09/2016 by Intellectual Property Watch 2 Comments What levers need to be pulled to improve access to medicine worldwide? Jayasree K. Iyer, Executive Director of the Access to Medicines Index, shares ideas that she says would lead to more people accessing the medicine they need.
Rebuttal Letter – WIPO Human Resources Report A “Whitewash” 07/09/2016 by Intellectual Property Watch 1 Comment Ed Flaherty writes: Please be advised that I represent the duly elected members of the World Intellectual Property Organisation’s Staff Council. On their behalf, I must respond to the inaccuracies contained in the article entitled: “WIPO Human Resources: All Is Harmony, Secretariat Says” published on the IP-Watch website on 29 August 2016. The HRMD report from which this article is lifted presents a whitewashed and totally unrealistic picture of the current situation at WIPO.
A Principle Of Balance: Top Official Explains India’s IP Policy 07/09/2016 by Intellectual Property Watch Leave a Comment Adopted in May, the first Indian intellectual property policy brought some concerns that the focus on IP rights might dampen India’s willingness to use the IP flexibilities to safeguard national policy space. It was also perceived by some as giving in to pressure from the foreign pharmaceutical industry for India to strengthen patent protection. However, a high level Indian official in an interview this week said the policy caters to Indian development needs and India is aware of its pioneering role in certain sectors like access to medicines. Rajiv Aggarwal, Joint Secretary at the Indian Department of Industrial Policy & Promotion Ministry of Commerce & Industry sat down with Intellectual Property Watch’s Catherine Saez to describe how India’s IP policy came into being, to what aim, what it is expected to change in the Indian IP landscape, and how Indian is standing fast to its principle of balance.